Publications

Found 6 results
Filters: Author is L.J. Yang  [Clear All Filters]
2016
Y. Yang, Yang, L. J., Deng, M. Z., Luo, Y. Y., Wu, S., Xiong, L., Wang, D., Liu, Y., Liu, H., Yang, Y., Yang, L. J., Deng, M. Z., Luo, Y. Y., Wu, S., Xiong, L., Wang, D., Liu, Y., Liu, H., Yang, Y., Yang, L. J., Deng, M. Z., Luo, Y. Y., Wu, S., Xiong, L., Wang, D., Liu, Y., and Liu, H., “MTHFR C677T and A1298C polymorphisms and risk of lung cancer: a comprehensive evaluation”, vol. 15, p. -, 2016.
Y. Yang, Yang, L. J., Deng, M. Z., Luo, Y. Y., Wu, S., Xiong, L., Wang, D., Liu, Y., Liu, H., Yang, Y., Yang, L. J., Deng, M. Z., Luo, Y. Y., Wu, S., Xiong, L., Wang, D., Liu, Y., Liu, H., Yang, Y., Yang, L. J., Deng, M. Z., Luo, Y. Y., Wu, S., Xiong, L., Wang, D., Liu, Y., and Liu, H., “MTHFR C677T and A1298C polymorphisms and risk of lung cancer: a comprehensive evaluation”, vol. 15, p. -, 2016.
Y. Yang, Yang, L. J., Deng, M. Z., Luo, Y. Y., Wu, S., Xiong, L., Wang, D., Liu, Y., Liu, H., Yang, Y., Yang, L. J., Deng, M. Z., Luo, Y. Y., Wu, S., Xiong, L., Wang, D., Liu, Y., Liu, H., Yang, Y., Yang, L. J., Deng, M. Z., Luo, Y. Y., Wu, S., Xiong, L., Wang, D., Liu, Y., and Liu, H., “MTHFR C677T and A1298C polymorphisms and risk of lung cancer: a comprehensive evaluation”, vol. 15, p. -, 2016.
2015
J. Yang, Liang, M. L., Yan, J. L., Yang, Y. Q., Liu, L., Liu, C., Yang, L. J., and Li, C. Y., “Expression of Magnaporthe oryzae genes encoding cysteine-rich proteins secreted during nitrogen starvation and interaction with its host, Oryza sativa”, vol. 14, pp. 17099-17108, 2015.
2012
M. L. Lai, Yang, L. J., Zhu, X. H., and Li, M., “A novel mutation of the DSRAD gene in a Chinese family with dyschromatosis symmetrica hereditaria”, vol. 11, pp. 1731-1737, 2012.
Alfadley A, Al AA, Hainau B, Pedersen KT, et al. (2000). Reticulate acropigmentation of Dohi: a case report of autosomal recessive inheritance. J. Am. Acad. Dermatol. 43: 113-117. http://dx.doi.org/10.1067/mjd.2000.103994 PMid:10863235   Cho DS, Yang W, Lee JT, Shiekhattar R, et al. (2003). Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J. Biol. Chem. 278: 17093-17102. http://dx.doi.org/10.1074/jbc.M213127200 PMid:12618436   Liu Q, Jiang L, Liu WL, Kang XJ, et al. (2006). Two novel mutations and evidence for haploinsufficiency of the ADAR gene in dyschromatosis symmetrica hereditaria. Br. J. Dermatol. 154: 636-642. http://dx.doi.org/10.1111/j.1365-2133.2006.07133.x PMid:16536805   Miyamura Y, Suzuki T, Kono M, Inagaki K, et al. (2003). Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am. J. Hum. Genet. 73: 693-699. http://dx.doi.org/10.1086/378209 PMid:12916015 PMCid:1180697   Murata I, Hayashi M, Hozumi Y, Fujii K, et al. (2010). Mutation analyses of patients with dyschromatosis symmetrica hereditaria: five novel mutations of the ADAR1 gene. J. Dermatol. Sci. 58: 218-220. http://dx.doi.org/10.1016/j.jdermsci.2010.04.001 PMid:20439151   O'Connell MA, Krause S, Higuchi M, Hsuan JJ, et al. (1995). Cloning of cDNAs encoding mammalian double-stranded RNA-specific adenosine deaminase. Mol. Cell Biol. 15: 1389-1397. PMid:7862132 PMCid:230363   Oiso N, Murata I, Hayashi M, Amatsu A, et al. (2011). Dermoscopic features in a case of dyschromatosis symmetrica hereditaria. J. Dermatol. 38: 91-93. http://dx.doi.org/10.1111/j.1346-8138.2010.01110.x PMid:21175763   Ostlere LS, Ratnavel RC, Lawlor F, Black MM, et al. (1995). Reticulate acropigmentation of Dohi. Clin. Exp. Dermatol. 20: 477-479. http://dx.doi.org/10.1111/j.1365-2230.1995.tb01382.x PMid:8857341   Oyama M, Shimizu H, Ohata Y, Tajima S, et al. (1999). Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi): report of a Japanese family with the condition and a literature review of 185 cases. Br. J. Dermatol. 140: 491-496. http://dx.doi.org/10.1046/j.1365-2133.1999.02716.x PMid:10233273   Rueter SM, Dawson TR and Emeson RB (1999). Regulation of alternative splicing by RNA editing. Nature 399: 75-80. http://dx.doi.org/10.1038/19992 PMid:10331393   Schade M, Turner CJ, Kuhne R, Schmieder P, et al. (1999). The solution structure of the Zalpha domain of the human RNA editing enzyme ADAR1 reveals a prepositioned binding surface for Z-DNA. Proc. Natl. Acad. Sci. U. S. A. 96: 12465-12470. http://dx.doi.org/10.1073/pnas.96.22.12465 PMid:10535945 PMCid:22950   Sun XK, Xu AE, Chen JF and Tang X (2005). The double-RNA-specific adenosine deaminase (DSRAD) gene in dyschromatosis symmetrica hereditaria patients: two novel mutations and one previously described. Br. J. Dermatol. 153: 342-345. http://dx.doi.org/10.1111/j.1365-2133.2005.06572.x PMid:16086746   Suzuki N, Suzuki T, Inagaki K, Ito S, et al. (2005). Mutation analysis of the ADAR1 gene in dyschromatosis symmetrica hereditaria and genetic differentiation from both dyschromatosis universalis hereditaria and acropigmentatio reticularis. J. Invest. Dermatol. 124: 1186-1192. http://dx.doi.org/10.1111/j.0022-202X.2005.23732.x PMid:15955093   Urabe K and Hori Y (1997). Dyschromatosis. Semin. Cutan. Med. Surg. 16: 81-85. http://dx.doi.org/10.1016/S1085-5629(97)80039-9   Wagner RW, Smith JE, Cooperman BS and Nishikura K (1989). A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and Xenopus eggs. Proc. Natl. Acad. Sci. U. S. A. 86: 2647-2651. http://dx.doi.org/10.1073/pnas.86.8.2647 PMid:2704740 PMCid:286974   Zhang XJ, Gao M, Li M, Li M, et al. (2003). Identification of a locus for dyschromatosis symmetrica hereditaria at chromosome 1q11-1q21. J. Invest. Dermatol. 120: 776-780. http://dx.doi.org/10.1046/j.1523-1747.2003.12130.x PMid:12713580
2011
B. Jiang, Zhu, Z. Z., Liu, F., Yang, L. J., Zhang, W. Y., Yuan, H. H., Wang, J. G., Hu, X. H., and Huang, G., “STAT3 gene polymorphisms and susceptibility to non-small cell lung cancer”, vol. 10, pp. 1856-1865, 2011.
Abdulghani J, Gu L, Dagvadorj A, Lutz J, et al. (2008). Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172: 1717-1728. http://dx.doi.org/10.2353/ajpath.2008.071054 PMid:18483213    PMCid:2408430 Barrett JC, Fry B, Maller J and Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265. http://dx.doi.org/10.1093/bioinformatics/bth457 PMid:15297300 Barrett JC, Hansoul S, Nicolae DL, Cho JH, et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet. 40: 955-962. http://dx.doi.org/10.1038/ng.175 PMid:18587394    PMCid:2574810 Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, et al. (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102. http://dx.doi.org/10.1016/j.ccr.2009.01.002 PMid:19185844 Bowman T, Garcia R, Turkson J and Jove R (2000). STATs in oncogenesis. Oncogene 19: 2474-2488. http://dx.doi.org/10.1038/sj.onc.1203527 PMid:10851046 Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, et al. (1999). Stat3 as an oncogene. Cell 98: 295-303. http://dx.doi.org/10.1016/S0092-8674(00)81959-5 Darnell JE (2005). Validating Stat3 in cancer therapy. Nat. Med. 11: 595-596. http://dx.doi.org/10.1038/nm0605-595 PMid:15937466 Dauer DJ, Ferraro B, Song L, Yu B, et al. (2005). Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397-3408. http://dx.doi.org/10.1038/sj.onc.1208469 PMid:15735721 Ferguson LR, Han DY, Fraser AG, Huebner C, et al. (2010). Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population. Mutat. Res. 690: 108-115. http://dx.doi.org/10.1016/j.mrfmmm.2010.01.017 PMid:20109474 Fletcher S, Drewry JA, Shahani VM, Page BD, et al. (2009). Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem. Cell Biol. 87: 825-833. http://dx.doi.org/10.1139/O09-044 PMid:19935868 Grivennikov SI and Karin M (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21: 11-19. http://dx.doi.org/10.1016/j.cytogfr.2009.11.005 Horinaga M, Okita H, Nakashima J, Kanao K, et al. (2005). Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 66: 671-675. http://dx.doi.org/10.1016/j.urology.2005.03.066 PMid:16140113 Hsieh FC, Cheng G and Lin J (2005). Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem. Biophys. Res. Commun. 335: 292-299. http://dx.doi.org/10.1016/j.bbrc.2005.07.075 PMid:16081048 Hsu HS, Huang PI, Chang YL, Tzao C, et al. (2011). Cucurbitacin i inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 117: 2970-2985. http://dx.doi.org/10.1002/cncr.25869 PMid:21225866 Ito N, Eto M, Nakamura E, Takahashi A, et al. (2007). STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25: 2785-2791. http://dx.doi.org/10.1200/JCO.2006.09.8897 PMid:17602083 Jing N, Zhu Q, Yuan P, Li Y, et al. (2006). Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol. Cancer Ther. 5: 279-286. http://dx.doi.org/10.1158/1535-7163.MCT-05-0302 PMid:16505101 Karin M (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436. http://dx.doi.org/10.1038/nature04870 PMid:16724054 Kreil S, Waghorn K, Ernst T, Chase A, et al. (2010). A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon alpha. Haematologica 95: 148-152. http://dx.doi.org/10.3324/haematol.2009.011510 PMid:20065083    PMCid:2805737 Lai SY and Johnson FM (2010). Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist. Updat. 13: 67-78. http://dx.doi.org/10.1016/j.drup.2010.04.001 PMid:20471303 Lin Q, Lai R, Chirieac LR, Li C, et al. (2005). Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am. J. Pathol. 167: 969-980. http://dx.doi.org/10.1016/S0002-9440(10)61187-X Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108. http://dx.doi.org/10.3322/canjclin.55.2.74 Sansone P, Storci G, Tavolari S, Guarnieri T, et al. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117: 3988-4002. http://dx.doi.org/10.1172/JCI32533 PMid:18060036    PMCid:2096439 Scagliotti GV, Longo M and Novello S (2009). Nonsmall cell lung cancer in never smokers. Curr. Opin. Oncol. 21: 99-104. http://dx.doi.org/10.1097/CCO.0b013e328321049e PMid:19532009 Shields PG (2002). Molecular epidemiology of smoking and lung cancer. Oncogene 21: 6870-6876. http://dx.doi.org/10.1038/sj.onc.1205832 PMid:12362269 Siddiquee K, Zhang S, Guida WC, Blaskovich MA, et al. (2007a). Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 104: 7391-7396. http://dx.doi.org/10.1073/pnas.0609757104 PMid:17463090    PMCid:1863497 Siddiquee KA, Gunning PT, Glenn M, Katt WP, et al. (2007b). An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem. Biol. 2: 787-798. http://dx.doi.org/10.1021/cb7001973 PMid:18154266 Stephens M, Smith NJ and Donnelly P (2001). A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68: 978-989. http://dx.doi.org/10.1086/319501 PMid:11254454 Turkson J (2004). STAT proteins as novel targets for cancer drug discovery. Expert. Opin. Ther. Targets. 8: 409-422. http://dx.doi.org/10.1517/14728222.8.5.409 PMid:15469392 Vaclavicek A, Bermejo JL, Schmutzler RK, Sutter C, et al. (2007). Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr. Relat. Cancer 14: 267-277. http://dx.doi.org/10.1677/ERC-06-0077 PMid:17639043 Weerasinghe P, Garcia GE, Zhu Q, Yuan P, et al. (2007). Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int. J. Oncol. 31: 129-136. PMid:17549413 Yang L, Parkin DM, Li LD, Chen YD, et al. (2004). Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br. J. Cancer 90: 2157-2166. PMid:15150609    PMCid:2409509 Yin W, Cheepala S, Roberts JN, Syson-Chan K, et al. (2006). Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol. Cancer 5: 15. http://dx.doi.org/10.1186/1476-4598-5-15 PMid:16603078    PMCid:1502137 Yin ZJ, Jin FG, Liu TG, Fu EQ, et al. (2010). Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. J. Surg. Res. Doi: 10.1016/j.jss.2010.03.053. http://dx.doi.org/10.1016/j.jss.2010.03.053 PMid:20605584 Yu H and Jove R (2004). The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4: 97-105. http://dx.doi.org/10.1038/nrc1275 PMid:14964307 Yu H, Pardoll D and Jove R (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9: 798-809. http://dx.doi.org/10.1038/nrc2734 PMid:19851315